New oral drug shows promise against deadly lassa fever
Disease control
Recruiting now
This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever in hospitalized adults in West Africa. About 135 participants will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is to see if the new…
Phase: PHASE2 • Sponsor: Arisan Therapeutics, Inc. • Aim: Disease control
Last updated Apr 24, 2026 09:14 UTC